2022-09-23 | NDAQ:PDSB | Press release

FLORHAM PARK, NJ, Sept. 23, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing portfolio of targeted immunotherapies for cancer and infectious diseases, announced today that PDS Biotech has obtained a non-statutory stock option license to (a) Amber King, PDS Biotech Clinical Trials Assistant, for the purchase of 5,000 common shares of PDS Biotech, (b) Charliene Casey, Associate Director of Data Management of PDS Biotech, to purchase 12,000 shares of PDS Biotech;s common stock, and (c) David Schaaf, Vice President of Medical Affairs of PDS Biotech, to purchase 70 000 shares of PDS Biotech common stock, in each case, as a material incentive for their employment with PDS Biotech and in accordance with Nasdaq listing rule 5635(c)(4) and PDS Biotech’s 2019 Incentive Plan, as amended, which was adopted on June 17, 201 9 and provides for the gran allocation of shares to new employees of PDS Biotech.

Each stock option has an exercise price of $3.18, the closing price of PDS Biotech common stock on September 22, 2022. Each stock option vests over a period of four years, with one-quarter of the shares vesting on the first anniversary of the grant date and the remaining shares vesting monthly over the following 36-month period, subject to continued employment with the company until the applicable vesting dates.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on the company’s proprietary Versamune.® and Infectimune™ T cell activation technology platforms. Our Versamune® demonstrated the potential to overcome the limitations of current immunotherapy by inducing live, large amounts of high-quality, highly potent, polyfunctional tumor-specific CD4+ killer T cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and attack and destroy them effectively. The Company’s pipeline products treat various cancers, including HPV16-associated cancers (anal, cervical, head and neck, penis, vaginal, vulvar) and breast, colon, lung, prostate and cervical cancers. ‘ovary.

Our Infectimune™-based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also potent T cell responses, including long-lasting memory T cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Forward-looking statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) regarding PDS Biotechnology Corporation ( the “Company”) and other matters. These statements may discuss objectives, intentions and expectations regarding future plans, trends, events, results of operations or financial condition, or otherwise, based on the current beliefs of the company’s management, as well as assumptions made by and information currently available. to management. Forward-looking statements generally include statements that are predictive in nature and depend on or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intention,” “forecast,” “direction,” “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions which are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statements due to a variety of factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash flow and the Company’s current expectations regarding its plans for future equity financings; the company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that the raising of such additional capital may restrict the company’s operations or require the company to waive its rights to the company’s products technologies or product candidates; the Company’s limited operating history in the Company’s current industry, which makes it difficult to assess the Company’s prospects, the Company’s business plan or the likelihood of successful implementation of this business plan by the Company; the timeline for the Company or its partners to initiate planned clinical trials for PDS0101, PDS0203 and other Versamunes® and Infectimune™-based product candidates; the future success of these trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaborative studies regarding PDS0101, PDS0203 and other Versamunes® and product candidates based on Infectimune™ and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and planned clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, rate of recruitment and completion trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material change in our currently projected expenditures), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any statements by the Company regarding its understanding of the mechanisms of action of product candidates and the interpretation of preclinical and early clinical results from its clinical development programs and any collaborative studies; and other factors, including legislative, regulatory, political and economic developments that are not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations resulting from or related to COVID-19 . The foregoing discussion of important factors that could cause actual events to differ from expectations should not be construed as complete and should be read in conjunction with the statements that are included herein and elsewhere, including the risk factors included in the company’s annual and periodic reports. filed with the SEC. Forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statement, whether as a result of new information, future events or otherwise.

Versamune® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology.

Investor contacts:

Deanne Randolph

PDS Biotech

Phone: +1 (908) 517-3613

drandolph@pdsbiotech.com

rich rooster

CG Capital

Phone: +1 (404) 736-3838

pdsb@cg.capital

Media

Dave Schemelia

Tiberend Strategic Advisors, Inc.

Phone: +1 (609) 468-9325

dschemelia@tiberend.com